|
|
Progress on molecular biomarkers and classification of malignant gliomas |
Chuanbao Zhang1, Zhaoshi Bao1, Wei Zhang1, Tao Jiang1,2() |
1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China; 2. Beijing Neurosurgical Institute, Beijing 100050, China |
|
|
Abstract Gliomas are the most common primary intracranial tumors in adults. Anaplastic gliomas (WHO grade III) and glioblastomas (WHO grade IV) represent the major groups of malignant gliomas in the brain. Several diagnostic, predictive, and prognostic biomarkers for malignant gliomas have been reported over the last few decades, and these markers have made great contributions to the accuracy of diagnosis, therapeutic decision making, and prognosis of patients. However, heterogeneity in patient outcomes may still be observed, which highlights the insufficiency of a classification system based purely on histopathology. Great efforts have been made to incorporate new information about the molecular landscape of gliomas into novel classifications that may potentially guide treatment. In this review, we summarize three distinctive biomarkers, three most commonly altered pathways, and three classifications based on microarray data in malignant gliomas.
|
Keywords
malignant glioma
molecular biomarker
IDH1
MGMT
molecular classification
|
Corresponding Author(s):
Jiang Tao,Email:jiangtao369@sohu.com
|
Issue Date: 05 June 2013
|
|
1 |
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97-109 doi: 10.1007/s00401-007-0243-4 pmid:17618441
|
2 |
Jones DT, Gronych J, Lichter P, Witt O, Pfister SM. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 2012; 69(11): 1799-1811 doi: 10.1007/s00018-011-0898-9 pmid:22159586
|
3 |
Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004; 14(2): 131-136 doi: 10.1111/j.1750-3639.2004.tb00045.x pmid:15193025
|
4 |
Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64(6): 479-489 pmid:15977639
|
5 |
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60(3): 166-193 doi: 10.3322/caac.20069 pmid:20445000
|
6 |
Lawrence YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J, Shen X, Symon Z, Dicker AP. Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 2012; 118(17): 4228-4234 pmid:22180310
|
7 |
Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z, Chen Y, Yao K, Zhang W, Kang C, Jiang T. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro-oncol 2012; 14(4): 518-525 doi: 10.1093/neuonc/nor232 pmid:22326863
|
8 |
Geisbrecht BV, Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 1999; 274(43): 30527-30533 doi: 10.1074/jbc.274.43.30527 pmid:10521434
|
9 |
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321(5897): 1807-1812 doi: 10.1126/science.1164382 pmid:18772396
|
10 |
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360(8): 765-773 doi: 10.1056/NEJMoa0808710 pmid:19228619
|
11 |
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174(4): 1149-1153 doi: 10.2353/ajpath.2009.080958 pmid:19246647
|
12 |
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15(19): 6002-6007 doi: 10.1158/1078-0432.CCR-09-0715 pmid:19755387
|
13 |
van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16(5): 1597-1604 doi: 10.1158/1078-0432.CCR-09-2902 pmid:20160062
|
14 |
Shibahara I, Sonoda Y, Kanamori M, Saito R, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Kato S, Ishioka C, Tominaga T. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 2012; 17(6): 551-561 pmid:21971842
|
15 |
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118(4): 469-474 doi: 10.1007/s00401-009-0561-9 pmid:19554337
|
16 |
Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010; 34(8): 1199-1204 doi: 10.1097/PAS.0b013e3181e7740d pmid:20661018
|
17 |
Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009; 68(12): 1319-1325 doi: 10.1097/NEN.0b013e3181c391be pmid:19915484
|
18 |
Ichimura K, Pearson DM, Kocialkowski S, B?cklund LM, Chan R, Jones DT, Collins VP. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncol 2009; 11(4): 341-347 doi: 10.1215/15228517-2009-025 pmid:19435942
|
19 |
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324(5924): 261-265 doi: 10.1126/science.1170944 pmid:19359588
|
20 |
Dang L, White D W, Gross S, Bennett B D, Bittinger M A, Driggers E M, Fantin V R, Jang H G, Jin S, Keenan M C, Marks K M, Prins R M, Ward P S, Yen K E, Liau L M, Rabinowitz J D, Cantley L C, Thompson C B, Vander Heiden M G, Su S M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462(7274):739-744 . doi: 10.1038/nature08617 pmid:19935646
|
21 |
Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 2011; 108(8): 3270-3275 doi: 10.1073/pnas.1019393108 pmid:21289278
|
22 |
Jeuken JW, von Deimling A, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 2004; 70(2): 161-181 doi: 10.1007/s11060-004-2748-1 pmid:15674476
|
23 |
Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, Yan H, Papadopoulos N, Kinzler KW. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333(6048): 1453-1455 doi: 10.1126/science.1210557 pmid:21817013
|
24 |
Scheie D, Cvancarova M, M?rk S, Skullerud K, Andresen PA, Benestad I, Helseth E, Meling T, Beiske K. Can morphology predict 1p/19q loss in oligodendroglial tumours? Histopathology 2008; 53(5): 578-587 doi: 10.1111/j.1365-2559.2008.03160.x pmid:18983467
|
25 |
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27(35): 5874-5880 doi: 10.1200/JCO.2009.23.6497 pmid:19901110
|
26 |
Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24(18): 2707-2714 doi: 10.1200/JCO.2005.04.3414 pmid:16782910
|
27 |
van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24(18): 2715-2722 doi: 10.1200/JCO.2005.04.6078 pmid:16782911
|
28 |
Kouwenhoven MCM, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJB, Brandes AA, van den Bent MJ. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 2006; 42(15): 2499-2503 doi: 10.1016/j.ejca.2006.05.021 pmid:16914310
|
29 |
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455(7216): 1061-1068 doi: 10.1038/nature07385 pmid:18772890
|
30 |
Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89(7): 2965-2969 doi: 10.1073/pnas.89.7.2965 pmid:1557402
|
31 |
Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 1992; 51(1): 84-90 doi: 10.1097/00005072-199201000-00010 pmid:1311022
|
32 |
Lino MM, Merlo A. PI3Kinase signaling in glioblastoma. J Neurooncol 2011; 103(3): 417-427 doi: 10.1007/s11060-010-0442-z pmid:21063898
|
33 |
Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009; 16(6): 748-754 doi: 10.1016/j.jocn.2008.12.005 pmid:19324552
|
34 |
Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010; 12(9): 675-684 pmid:20824044
|
35 |
Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004; 63(7): 700-707 pmid:15290895
|
36 |
Knobbe CB, Merlo A, Reifenberger G. Pten signaling in gliomas. Neuro Oncol 2002; 4(3): 196-211 pmid:12084351
|
37 |
Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009; 100(12): 2235-2241 doi: 10.1111/j.1349-7006.2009.01308.x pmid:19737147
|
38 |
Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther 2008; 7(9): 1321-1325 doi: 10.4161/cbt.7.9.6954 pmid:18836294
|
39 |
Busch C, Geisler J, Knappskog S, Lillehaug JR, L?nning PE. Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine. J Invest Dermatol 2010; 130(10): 2514-2516 doi: 10.1038/jid.2010.138 pmid:20505745
|
40 |
Silber JR, Bobola MS, Blank A, Chamberlain MC. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta 2012; 1826(1): 71-82 pmid:22244911
|
41 |
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10): 997-1003 doi: 10.1056/NEJMoa043331 pmid:15758010
|
42 |
Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol 2011; 105(2): 325-335 doi: 10.1007/s11060-011-0594-5 pmid:21523485
|
43 |
Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008; 9(1): 29-38 doi: 10.1016/S1470-2045(07)70384-4 pmid:18082451
|
44 |
Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-oncol 2010; 12(2): 116-121 doi: 10.1093/neuonc/nop020 pmid:20150378
|
45 |
Minniti G, Salvati M, Arcella A, Buttarelli F, D’Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 2011; 102(2): 311-316 doi: 10.1007/s11060-010-0324-4 pmid:20686820
|
46 |
Combs SE, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 2011; 6(1): 115 doi: 10.1186/1748-717X-6-115 pmid:21910919
|
47 |
Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-oncol 2010; 12(3): 283-288 doi: 10.1093/neuonc/nop050 pmid:20167816
|
48 |
Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10(6): 1871-1874 doi: 10.1158/1078-0432.CCR-03-0384 pmid:15041700
|
49 |
van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009; 27(35): 5881-5886 doi: 10.1200/JCO.2009.24.1034 pmid:19901104
|
50 |
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9(3): 157-173 doi: 10.1016/j.ccr.2006.02.019 pmid:16530701
|
51 |
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1): 98-110 doi: 10.1016/j.ccr.2009.12.020 pmid:20129251
|
52 |
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96(15): 8681-8686 doi: 10.1073/pnas.96.15.8681 pmid:10411935
|
53 |
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17(5): 510-522 doi: 10.1016/j.ccr.2010.03.017 pmid:20399149
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|